Measuring Protein Mobility with Electrophoretic Light Scattering - The author describes a method to avoid protein aggregation when using light scattering systems. - BioPharm International

ADVERTISEMENT

Measuring Protein Mobility with Electrophoretic Light Scattering
The author describes a method to avoid protein aggregation when using light scattering systems.


BioPharm International
pp. 20-23

DIFFUSION BARRIER TECHNIQUE

Work by Corbett et al. (1) has shown that much of the aggregation that occurs during electrophoretic measurements of proteins in solution takes place at the electrodes. Standard guide ASTM E2865 (2), published in 2012, deals with the measurement of mobility and zeta potential in systems containing biological material such as proteins, DNA, liposomes, and other similar organic materials that possess particle sizes in the nanometer scale, below 100 nm. It indicates that these molecules can be quite labile and may absorb and decompose under an electrical field, and goes on to say that it is virtually impossible to eliminate such decomposition for some molecules unless specific routes are taken, such as isolating the electrodes from the biological molecules.


Figure 1: Folded capillary cells. Left—filled with blue dextran in 10 mM NaCl, and right—filled with 10 mM NaCl and loaded with 50 μL blue dextran for measurement using the diffusion barrier technique. (ALL FIGURES ARE COURTESY OF MALVERN INSTRUMENTS)
The diffusion barrier technique described here separates the sample molecules from the electrodes, minimizing the effect of the measurement technique itself on the sample. As a result, the voltage can be applied for a longer period to generate more data from the measurement. A folded capillary cell allows the introduction of approximately 20 μL sample, that is then separated from the electrodes by the same buffer in which the protein is dissolved (Figure 1). By creating this physical separation, the sample is protected for as long as it takes to diffuse to the electrodes, which may be many hours.

EXAMPLE MEASUREMENT

In experiments conducted by application scientists at Malvern Instruments' headquarters in the UK, human serum albumin (HSA) was prepared in different buffers to a final concentration of approximately 2 mg/mL. The buffers were the original formulation buffer at pH 7 and a citrate buffer at pH 4.3. Samples were filtered to ensure there were no aggregates present at the start of the measurement. The diffusion barrier technique was performed by filling a disposable capillary cell with the appropriate buffer and then loading 20 μL of the diluted HSA into the optical area at the bottom of the cell with a gel-loading pipette tip. Size and mobility measurements were made in the Zetasizer Nano ZSP. The hydrodynamic size and mobility of HSA were measured using DLS and ELS, respectively. Both were measured at the same scattering angle to use the size results to confirm that mobility results corresponded with the protein and not with any aggregated material.


Figure 2: (A) Overlaid size measurement showing human serum albumin (HAS) at pH 7 before the mobility measurement. (B) Overlaid frequency plots during mobility measurement at pH 7. (C) Overlaid size measurements showing HSA at pH 7 after the mobility measurements. (D) Overlaid size measurement showing HSA at pH 4.3 before the mobility measurement. (E) Overlaid frequency plots during mobility measurement at pH 4.3. (F) Overlaid size measurements showing HSA at pH 4.3 after the mobility measurements.
Figures 2A and 2D show the size distributions at the beginning of the experiment for samples at pH 7 and pH 4.3, respectively, and exhibit the single peaks expected from the filtered samples. Figures 2B and 2E are frequency plots from mobility measurements.

These are useful in assessing measurement quality as they show the distribution of frequencies in the scattered light (3). Proteins have a significant Brownian component in their overall mobility, so the peak in the frequency plot is expected to be broad. Aggregates in the sample will have lower Brownian motion, resulting in a sharp peak in the frequency plot. The presence of a broad peak in the frequency plot is, therefore, indicative of high quality data whereas a frequency plot containing a sharp peak is highly likely to contain information derived from aggregates. In the results shown here, the broad shallow peaks from both samples indicate that the measurement is primarily of the protein and not aggregates.

The overall charge from the hydrodynamic size and electrophoretic mobility was calculated by the instrument software. The calculated charge for HSA at pH 7 was approximately -18 and at pH 4.3 approximately +10.

Figures 2C and 2F show the size distributions of the samples after the mobility measurements had been made and indicate that only a very small amount of aggregation occurred. In both cases, the primary peak was the dominant peak, accounting for 99% of the scattered light at pH 7 and 90% at pH 4.3. The results from these mobility measurements, therefore, have high confidence. The pH 4.3 sample was shown to be aggregating over time in the absence of an electric field; this is most likely because of its low pH and also accounts for the small amount of aggregation occurring in this sample during the measurement.

In conclusion, the mobility of HSA was measured successfully in different buffers at a concentration of 2 mg/mL and using a 20 μL sample.

Stephen Ball is product marketing manager, nanoparticle and molecular characterization, Malvern Instruments Ltd, Enigma Business Park, Grovewood Road, Malvern, WR14 1XZ UK, tel 44 (0) 1684 892456;
.

REFERENCES

1. J. Corbett, M. Connah, and K. Mattison, Electrophoresis, 32 (14), 1787-94 (2011).

2. ASTM, ASTM E2865–Standard Guide for Measurement of Electrophoretic Mobility and Zeta Potential of Nanosized Biological Materials (West Conshohocken, PA, 2012).

3. Malvern application note: The Diffusion Barrier Technique, Practical Aspects and Data interpretation, http://www.malvern.com/diffusion-barrier (accessed April 10, 2013).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here